Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder (OCD)

This study has been terminated.
(Study completed and data was inconclusive.)
Sponsor:
Information provided by (Responsible Party):
James G.Sullivan, MD, Parkway Medical Center
ClinicalTrials.gov Identifier:
NCT00997087
First received: October 14, 2009
Last updated: April 18, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)